Physician profile
Lynn Miller
NPI 1942592035
$1,917.06
in general payments reported to CMS, 2019-2025
29 companies · $753 in 2025
The $753 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $306 · 2023: $421 · 2024: $195 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.15 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.00 | 2022-2025 | |
| Novo Nordisk INC | $361.45 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $140.32 | 2023-2025 | |
| Amgen INC. | $127.80 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $89.70 | 2021-2025 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.03 | 2023-2025 | Caplyta |
| Scpharmaceuticals INC. | $64.26 | 2025 | |
| Glaxosmithkline, LLC. | $63.58 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $57.55 | 2021-2025 | Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.02 | 2021-2022 | |
| Alkermes, INC. | $49.96 | 2025 | Vivitrol |
| Sunovion Pharmaceuticals INC. | $40.53 | 2021 | |
| Organon LLC | $38.78 | 2021-2023 | Nexplanon |
| Edwards Lifesciences Corporation | $33.48 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $28.05 | 2025 | Farxiga, Brilinta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $22.94 | 2025 | Sublocade |
| Biohaven Pharmaceutical Holding Company LTD. | $22.13 | 2022 | |
| Lundbeck LLC | $22.02 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $21.30 | 2024 | |
| Jazz Pharmaceuticals INC. | $20.94 | 2021 | |
| Corcept Therapeutics | $20.80 | 2025 | Korlym |
| Vbi Vaccine (Delaware) INC. | $20.69 | 2022 | |
| Axsome Therapeutics, INC. | $20.50 | 2025 | Auvelity |
| Hologic Sales and Service, LLC | $19.10 | 2025 | Aptima, Thinprep 2000 Processor |
| Biohaven Pharmaceuticals, INC. | $18.07 | 2021 | |
| Phadia US INC. | $17.89 | 2024 | Immunocap |
| Novartis Pharmaceuticals Corporation | $13.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.05 | 2022 | |
| Exact Sciences Corporation | $12.93 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.